Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 99

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 99
---
 exercise the licensing option and finalize the related terms. If results do not meet established thresholds, we do not intend to exercise
the option. If no agreement is reached within the negotiation period, Yissum shall have no further obligations to the Company with respect
to the technology.

ARBs is a class of drugs that block the Angiotensin
II Type 1 receptor (AT1), which is involved in the regulation of blood pressure, fluid balance, and inflammation. ARBs have been widely
used for the treatment of hypertension, heart failure, and diabetic nephropathy. Several recent studies have shown that ARBs may have
certain anti-cancer enhancement features. Among other, ARBs can inhibit proliferation, migration, invasion, and angiogenesis of tumor
cells, as well as induce apoptosis and autophagy. ARBs may also modulate the immune response by affecting the polarization and activation
of macrophages, T cells, and natural killer cells.

By “combination therapy” we refer
to the administration of nano-candesartan with other oncology agents, such as approved chemotherapy drugs and/or immune checkpoint inhibitors
(immunotherapy agents such as Keytruda).

Novel formulation of Nanoparticles-based ARB
(nano-ARB) was designed to improve the therapeutic outcome of chemotherapy and biological treatments, such as antibodies and immune checkpoint
inhibitors for solid cancers. Solid cancers, such as breast, lung, colon, pancreas and prostate cancers, present a formidable challenge
to oncologists, as they are often resistant to existing treatments and have poor prognosis. One major obstacle lies in the complex tumor
microenvironment (TME), which consists of various cellular and non-cellular components that interact with each other and with the tumor
cells. The TME creates a physical and immunological barrier that impairs the delivery and effectiveness of anti-cancer drugs. For example,
the tumor blood vessels are leaky and irregular, resulting in poor perfusion and hypoxia. The extracellular matrix (ECM) within the TME
is dense and fibrotic, making it difficult for drugs to penetrate and reach their intended targets. The TME also contains various immune
cells, such as macrophages, T cells, and natural killer cells, that can either suppress or enhance the anti-tumor immune response, depending
on their polarization and activation state.

To overcome the challenges posed by the TME, nano-ARB
is targeting one of the key cellular structures in the TME